Sermorelin

Sermorelin — Growth Hormone-Releasing Hormone Analog for Endocrine Research

Sermorelin (GHRH 1-29 NH₂) is a synthetic peptide analog corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44), which retains full biological activity at the GHRH receptor. Originally developed at Tulane University by Nobel laureate Roger Guillemin's group and subsequently approved by the FDA for diagnostic use (Geref®), Sermorelin has served as a foundational research tool in neuroendocrine physiology for over three decades. Its well-characterized pharmacology and established safety profile in clinical studies make it one of the most extensively studied GH secretagogues in the peptide research field.

Mechanism of Action

Sermorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating the Gsα/adenylyl cyclase/cAMP/PKA signaling cascade. This triggers GH gene transcription, GH granule exocytosis, and somatotroph cell proliferation. Unlike direct GH administration, Sermorelin preserves the physiological pulsatile GH secretion pattern and maintains negative feedback via IGF-1 and somatostatin. The compound's 29-amino acid structure represents the minimum active fragment of GHRH, with the C-terminal amidation enhancing receptor binding affinity and proteolytic stability compared to the native hormone.

Key Research Areas

• GH Axis Physiology: Sermorelin remains the standard GHRH receptor agonist for pituitary function testing, enabling researchers to assess somatotroph reserve capacity, GHRH receptor expression, and hypothalamic-pituitary feedback integrity in both normal and pathological models.
• Age-Related GH Decline: Research has documented that Sermorelin restores pulsatile GH secretion amplitude in aged animal models, normalizing IGF-1 levels and improving body composition parameters (lean mass/fat mass ratio) without the supraphysiological effects of exogenous GH.
• Synergistic Secretagogue Studies: Researchers frequently combine Sermorelin with GHRP-class peptides (GHRP-2, GHRP-6, Ipamorelin) to study the synergistic amplification of GH release through simultaneous GHRH receptor and ghrelin receptor activation.
• Sleep and Circadian Research: EEG-monitored studies have demonstrated that Sermorelin enhances slow-wave sleep duration and delta wave power in both young and aged subjects, correlating with augmented nocturnal GH pulse amplitude.

Technical Specifications

• Dosage per vial: 2mg lyophilized powder
• Purity: ≥98% (HPLC verified)
• Sequence: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
• Molecular Weight: 3,357.88 Da
• Storage: -20°C, protected from light

Why Researchers Choose Peptides BioLab

Every batch of Sermorelin supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.

Related Research Peptides

Researchers studying the GH axis may also find these compounds relevant: CJC-1295, Ipamorelin, and GHRP-2. For a complete overview, browse our Growth Hormone Research collection.

For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.